<DOC>
	<DOCNO>NCT02641028</DOCNO>
	<brief_summary>A Randomized , Double-Blind , Placebo-Controlled , Crossover Design Study CERC-501 Human Laboratory Model Smoking Behavior .</brief_summary>
	<brief_title>A Study Human Laboratory Model Smoking Behavior</brief_title>
	<detailed_description>The study perform subject heavy cigarette smoker currently seek treatment tobacco use disorder . The study crossover design study ( within-subject analysis ) , allow subject control . Each period crossover consist 7-day out-patient treatment period follow single in-patient testing day Day 8 . Subjects participate laboratory session follow McKee Smoking Lapse Test discharge clinic undergo 7 day washout period follow second period crossover design 7-day follow-up visit .</detailed_description>
	<criteria>1 . Provides write informed consent agree complete require clinic visit 2 . Male female 21 60 year age inclusive 3 . Body mass index ( BMI ) 18.5 40 kg/m2 inclusive 4 . Heavy Smokers 5 . Currently seek smoke cessation therapy 6 . In otherwise good general health without unstable medical condition ( determine medical history , medication history , physical examination , 12lead ECG , vital sign , clinical laboratory test ) 7 . Able read , write , speak English 8 . Females must either : Postmenopausal ( amenorrhea least 12 consecutive month ) , surgically sterile Women childbearing potential ( WOCBP ) must meet criterion : Uses acceptable doublebarrier method contraception determine Investigator Is lactate , negative serum beta human chorionic gonadotropin pregnancy test screen negative urine pregnancy test prior dose Days 1 8 treatment period . 9 . Male subject must agree use condom partner childbearing potential Subjects meet follow criterion eligible study : 1 . Any substance use disorder nicotine caffeine assess Diagnostic Statistical Manual Mental Disorders , Fifth Edition ( DSMV ) substance use disorder checklist addition MiniInternational Neuropsychiatric Interview ( MINI ) ( capture DSMV substance use disorder diagnosis ) 2 . Current neurological condition interfere study conduct , assessment treatment significant fashion 3 . Any lifetime history bipolar I , II ; schizophrenia psychotic disorder ; personality disorder , impulse control disorder assess MINI 4 . Current psychiatric condition interfere study conduct , assessment treatment significant fashion , major depressive disorder ( MDD ) , eat disorder , posttraumatic stress disorder , etc. , without permission medical monitor 5 . Recent active past history gastric disease peptic ulcer disease , gastritis , upper gastrointestinal bleeding , gastrointestinal malignancy precancerous condition 6 . Active , comorbid disease might limit ability subject participate study determine Investigator ( i.e. , poorly control diabetes mellitus , congestive heart failure , etc . ) 7 . Clinically significant clinical laboratory test take screening , without permission Medical Monitor 8 . Elevated AST ALT â‰¥ 2 time upper limit normal ( ULN ) 9 . Human immunodeficiency virus ( HIV ) , Hepatitis B Hepatitis C positive determine serology test Screening 10 . History severe allergy multiple adverse drug reaction 11 . Known hypersensitivity CERC501 12 . Current use proton pump inhibitor histamine 2 blocker without permission Medical Monitor 13 . Use investigational medication within 2 month prior start study schedule receive investigational drug study drug course study</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>